More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

On Wednesday, Goldman Sachs maintained a Buy rating on Pfizer Inc ... primarily due to strong sales of its COVID-19 treatment, Paxlovid. Despite the positive financial results, Pfizer's shares ...

Executive Editor David Carnoy has been a leading member of CNET's Reviews team since 2000. He covers the gamut of gadgets and is a notable reviewer of mobile accessories and portable audio ...

Browse our 8 Best Buy promo codes for savings on technology, from computers & cell phones to game consoles & appliances. All coupon content is created by TechRadar. We may earn a commission if you ...

On Wednesday, Goldman Sachs (NYSE:GS) maintained a Buy rating on Pfizer Inc. (NYSE: NYSE:PFE) shares, while increasing the stock's price target to $33.00 from $32.00. The adjustment follows Pfizer's ...

On Wednesday, Goldman Sachs maintained a Buy rating on Pfizer Inc. (NYSE: NYSE:PFE) shares, while increasing the stock's price target to $33.00 from $32.00. The adjustment follows Pfizer's ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...